Page 11 - Nancy Leone News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Harmony Biosciences Appoints Sandip Kapadia as Chief Financial Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Harmony Biosciences Certified As A Great Place To Work For The Third Year In A Row
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 17, 2020 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the Company will be added to the Russell 2000® and Russell 3000® Indexes effective after the U.S. market closes on Friday, December 18. Inclusion in the Russell 2000® and Russell 3000® Indexes is an important milestone for Harmony, said John C. Jacobs, Harmony s President and Chief Executive Officer. We believe it will enhance Harmony s visibility in the investment community and broaden our shareholder base.
Share this article
Share this article
PLYMOUTH MEETING, Pa. and CHICAGO, Dec. 15, 2020 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome (PWS). We view pitolisant as a portfolio in a product opportunity and are taking a mechanism-based approach to drug development in managing its life cycle with the goal of expanding its clinical utility, said Harmony s Chief Medical Officer, Jeffrey Dayno, M.D. We believe pitolisant could offer an important therapeutic benefit in people living with PWS based on preclinical models of the disorder, pitolisant s